Patent Wars: A New Hope (or, the Inventor Strikes Back!)

In this article, we discuss key parts of a recent UK decision and the implications for UK businesses and multinationals with employees carrying out R&D in the UK.  Although there is no corresponding right under Australian law, we also look at best practice for Australian businesses in securing ownership of inventions and other intellectual property rights and related compensation considerations. read more...
Subjects: Patents

Partner:

Manner of manufacture and software-based inventions: Patent eligibility test re-affirmed but limited further clarity provided by Australian Appeals Court

After much anticipation and a 10 month wait since the appeal was heard in November 2018, the expanded panel of five Federal Court judges in Encompass Pty Ltd v Infotrack Pty Ltd have delivered their decision, finding that they were “not persuaded that the primary judge erred in concluding that each [Encompass patent in suit] does not claim an invention that is a manner of manufacture within the meaning of section 6 of the Statute of Monopolies”.  Each of the Encompass patents in suit have accordingly been found to be invalid. read more...
Subjects: Patents

Manner of manufacture and software-based inventions: What does it mean for an invention to involve “an improvement in the computer”?

Whether inventions relating to the use of a computer are patentable according to the ‘manner of manufacture’ test has for many years been unclear in Australia.  This uncertainty, together with inconsistencies in how the law has been applied by the courts and the Australian Patent Office (APO), were just some of the contentious issues recently considered by a full bench of five judges from the Federal Court in Encompass Corporation Pty Ltd v InfoTrack Pty Ltd (NSD 734/2018) read more...
Subjects: Patents

A very modest win: Generic Health gets 2% cut to Bayer’s $25 million damages

Last year, Bayer was awarded more than $25 million (plus interest and indemnity costs) against Generic Health in the first Federal Court award of damages for pharmaceutical patent infringement.  In the appeal by Generic Health, the Full Court of the Federal Court allowed Generic Health a 2% discount to the $25 million damages originally awarded. What made the FCFCA give Generic Health such a modest discount? read more...
Subjects: Patents

United States Court of Appeals upholds PTAB decision on CRISPR Patent Interference

The interference action between the University of California (UC) and Broad Institute (Broad) has seemingly come to an end, with the United States Court of Appeals for the Federal Circuit Court (CAFC) affirming that the patent claims that had been granted to Broad in relation to its CRISPR/Cas9 gene editing patents are separately patentable from the claims of a patent application made by UC. read more...
Subjects: Patents

Promises, promises: Full Federal Court of Australia finds invention useful in ESCO Corporation v Ronneby Road

We can all be guilty of promising more than we can deliver – but for a patentee, that can be fatal for the validity of your patent.  Under Australian patent law, inventions must be ‘useful’ in order to be patentable, and one of the complex elements of this requirement is whether any promises made with read more...
Subjects: Patents

Partner:

Biotech Insights: 2018 industry snapshot and key trends

With the latest Scientific American, Worldwide Scorecard ranking Australia in the top five bio-economies globally, Australia’s biotechnology and life sciences sector continues to show healthy performance for the fifth consecutive year.  Despite the challenges of the global economy, there has been generally positive sentiment from an industry that is expected to continue growing, reaching close read more...